We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Cases · June 11, 2021

Patient With mCRPC With BRCA1+ and High Tumor Mutational Burden

Written by
Pedro C. Barata MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Noureddine Benjaafar


  • Charles Maack

    Olaparib, but if not effective, Docetaxel plus carboplatin

  • Noureddine Benjaafar

    Olaparib because of BRCA1 mutation

  • phil capozzi

    Olaparib for BRCA mutation

  • Syamsu Hudaya


  • Aug 06, 2021

    Pending Moderator approval.

Further Reading